Increased M1/decreased M2 signature and signs of Th1/Th2 shift in chronic patients with bipolar disorder, but not in those with schizophrenia by P. Brambilla et al.
OPEN
ORIGINAL ARTICLE
Increased M1/decreased M2 signature and signs of Th1/Th2
shift in chronic patients with bipolar disorder, but not in those
with schizophrenia
P Brambilla1,2, M Bellani3, M Isola4, A Bergami5, V Marinelli3, N Dusi3, G Rambaldelli3, M Tansella3, A Maria Finardi5, G Martino5,
C Perlini3 and R Furlan5
We here present data on immune gene expression of chemokines, chemokine receptors, cytokines and regulatory T-cell (T-reg) markers
in chronic patients suffering from either schizophrenia (SCZ, N= 20) or bipolar disorder (BD = 20) compared with healthy controls
(HCs, N= 20). We extracted RNA from peripheral blood mononuclear cells and performed real-time (RT)-PCR to measure mRNA
levels of chemokines, chemokine receptors, cytokines and T-reg markers. All the analyses were Bonferroni-corrected. The classical
monocyte activation (M1) markers il6, ccl3 were signiﬁcantly increased in BD as compared with both HC and SCZ patients (P= 0.03
and P= 0.002; P= 0.024 and P= 0.021, respectively), whereas markers of alternative (M2) monocyte activation ccl1, ccl22 and il10
were coherently decreased (controls: P= 0.01, P= 0.001 and P= 0.09; SCZ subjects: P= 0.02, P= 0.05 and P= 0.011, respectively).
Concerning T-cell markers, BD patients had compared with HC downregulated ccr5 (P= 0.02) and upregulated il4 (P= 0.04) and
compared with both healthy and SCZ individuals downregulated ccl2 (P= 0.006 and P= 0.003) and tgfβ (P= 0.004 and P= 0.007,
respectively). No signiﬁcant associations were found between any immune gene expression and clinical variables (prior
hospitalizations, Brief Psychiatric Rating Scale, medications’ dosages and lifetime administration). Although some markers are
expressed by different immune cell types, these ﬁndings suggest a coherent increased M1/decrease M2 signature in the peripheral
blood of BD patients with potential Th1/Th2 shift. In contrast, all the explored immune marker levels were preserved in SCZ. Further
larger studies are needed to investigate the relevance of inﬂammatory response in BD, trying to correlate it to psychopathology,
treatment and outcome measures and, possibly, to brain connectivity.
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INTRODUCTION
The immune system is considered a key factor in brain home-
ostasis and plasticity.1 Immune response can be achieved by the
innate or the adaptive immune response, both of which include
the activation of leukocytes. Cytokines represent the signal for
communication between leukocytes. Brieﬂy, the innate immune
system induces a fast and general immune response and includes
cells (that is, monocytes and macrophages) and soluble mediators,
whereas the adaptive system is slower but more speciﬁc and the
main component of it are B and T lymphocytes (the complement
system and cytokines; for a detailed description see Sperner-
Unterweger2). Cytokines are therefore the key signaling molecules
of the immune system and regulators of inﬂammation.
Inﬂammation and immunity have been recently proposed as
potential components of the etiology of schizophrenia (SCZ) and
bipolar disorder (BD).3–5 Hope et al.6 found no major differences in
BD and SCZ patients compared with healthy controls (HCs) except
for an increase in the plasma level of soluble TNF-receptor 1 and
von Willebrand factor in both types of patients. In contrast, other
authors7,8 found only interleukin 1β (IL1β) to be increased in BD,
as compared with HC, whereas IL1β, IL-6, tumor necrosis factor α
(TNFα) and CCL2 were all increased, as compared with HC, in SCZ
patients. Some recent lines of evidence demonstrated the
presence of both pro-inﬂammatory activation of the innate
immune system and of the T cells of the adaptive immune
system in SCZ and BD,9,10 showing that levels of soluble TNF-
receptor 1, IL-1Ra, osteoprogesterin and IL-6 are state-related for
BD but not in patients with SCZ. This ﬁnding would suggest a
different immunological pattern in the two diseases.
Concerning SCZ, a putative role in its etiopathogenesis was
already proposed 40 years ago11 and led to the hypothesis of a
possible cytokine imbalance. Indeed, some investigations demon-
strated alterations in circulating inﬂammatory cytokine levels in
patients with SCZ12,13 and their relatives,14–16 but other studies
had controversial results.17–21 Recently, a population-based study
found IL-1 receptor antagonist to be marker of metabolic
comorbidity, rather than of an inﬂammatory etiology in SCZ.22
Few studies have been conducted in BD that found a lack of
T-regulatory (T-reg) cells and an overall inﬂammatory gene
expression 'signature' in the circulating monocytes8,9,23 including
PDE4B, IL1B, IL6, TNF, TNFAIP3, PTGS2, PTX3, CCL2, CCL7, CCL20,
CXCL2, CCR2 and CDC42. Moreover, acute symptomatology has
been associated with higher levels of pro-inﬂammatory cytokines
(IL-1Ra, IL-8, IL-4, C reactive protein, TNF-α and IL-6)13,24–27 but not
in all studies.28,29 There is however a lack of studies exploring BD,
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and, due to methodology variability and small sample sizes,
ﬁndings are still controversial. However, recent meta-analyses
have conﬁrmed the importance of cytochine alterations in BD.30 In
this regards, it should be noted that cytokines and chemokines
control both the trafﬁc of immune cells into the central nervous
system and the formation of perivenular inﬂammatory inﬁltrates,
which may lead to demyelination and axonal loss.31,32 Moreover, it
has been shown that pro-inﬂammatory cytokines are associated
with cognitive disturbance in humans33 and that, in rodents,
T cells are needed for normal cognitive functioning.34 Therefore,
an altered immune system may potentially affect brain con-
nectivity, and cognition, having a major role in the
pathophysiology of BD.
In order to test the hypothesis of an immunological activation in
BD, the objective of the current study was to investigate whether
the levels of inﬂammatory parameters in a sample of chronic BD
are different compared with chronic SCZ and HC.
MATERIALS AND METHODS
Participants
Three groups of participants were enrolled in the study. The ﬁrst group
included 20 outpatients with clinical diagnosis of SCZ (14 males, 6 females;
mean age= 39.75 ± 7.86). The second group was composed of 20
outpatients with BD (7 males, 13 females; mean age = 42.45 ± 6.58).
The two groups of patients were selected from the South-Verona
Psychiatric Case Register,35 a community-based mental health register that
refers to the four Psychiatric Services of Verona. Diagnoses of SCZ and BD
were established according to the DSM-IV criteria, using the Structural
Clinical Interview for DSM-IV, SCID-I, Italian version36 and subsequently
conﬁrmed with the clinical consensus of two staff psychiatrists. Clinical
consensus of two staff psychiatrists was also regularly taken into account in
order to double-check all the diagnoses, according to the DSM-IV criteria.
Patients with other Axis I disorders, alcohol or substance abuse, history of
traumatic head injury, neurological or medical diseases and mental
retardation were excluded from the study.
Additional exclusion criteria for the patient group were: electroconvul-
sive therapy during 6 months before the recruitment and treatment with
immunomodulatory drugs in the prior 6 months, pregnancy, head injury
with loss of consciousness, family history of hereditary neurologic disorder
or ﬂoating metallic objects in the body. Symptoms at the moment of the
assessment (in the same day or within 1 week) were evaluated by
administering the Brief Psychiatric Rating Scale37 for SCZ and BD patients,
whereas only for the BD group manic or depressive symptoms were
characterized by using the Bech–Rafaelsen Mania Rating Scale (BRMRS)
and the Hamilton Depression Rating Scale (HAM-D), respectively.38
The third group included 20 HCs (9 males, 11 females; mean
age= 36.6 ± 7.69) with no DSM-IV Axis I and Axis-II disorders, no history
of psychiatric disorders among their ﬁrst-degree relatives, no history of
alcohol or substance abuse, no history of head injury and no current
neurological or medical illness, including hypertension and diabetes. The
absence of psychiatric disturbances was determined by a brief interview
modiﬁed from the SCID-IV non-patient version.39 Sociodemographic and
clinical data of the three groups are outlined in Table 1. Except for three
patients on treatment with clopixol, all patients with SCZ were receiving
atypical antipsychotic medications: four olanzapine, four clozapine, four
risperidone, three quetiapine, two aripiprazole. Three of them were
receiving also haloperidol in combination with the atypical. All BD
participants but three were receiving medications at the time of
assessment. Speciﬁcally, four patients were on atypical neuroleptics
(olanzapine), ﬁve were on typical neuroleptics (two haloperidol and three
clotiapine), four patients were on antidepressant medications (one
citalopram, one ﬂuoxetine, one imipramine and one escitalopram); 11 of
BD patients were taking one mood stabilizer (one oxcarbamazepine, four
lithium, four valproic acid and two lamotrigine).
As for BD, based on the HAM-D, eight had mild depression (HAM-D score
between 8 and 17), four had moderate depression (HAM-D score between
18 and 24) and one had severe depression (HAM-D score ⩾ 25). On the
basis of the BRMRS, three BD patients had a hypomania state (BRMRS score
between 8 and 24). On the basis of both HAM-D and BRMRS, ﬁve patients
were euthymic (HAM-D score ⩽ 7; BRMRS score ⩽ 7) and two were in a
mixed state (HAM-D score 47; BRMRS score 47).
All control participants were recruited in the Hospital/University and in
the community areas by word of mouth and through advertisements.
Informed consent was obtained from all participants after they had
understood the aims and the procedures of the study and the issues
involved in study participation. The study was approved by the Ethical
Committee of the Azienda Ospedaliera Universitaria Integrata of Verona.
RNA extraction and complementary DNA (cDNA) synthesis
Blood has been collected in PAXgene Blood RNA Tubes (Qiagen, Milano,
Italy). RNA has been extracted using PAXgene Blood RNA Kit (Qiagen),
according to the manufacturer's protocol. cDNA has been synthesized from
3–5 μg of RNA using a random hexamer-primed kit (Ready-to-go,
Amersham Bioscience, Milan, Italy). Blood samples were collected in the
morning, and the subjects were asked not to drink coffee or smoke
cigarettes before the blood draw.
Table 1. Description of populations’ features
Controls (N= 20) Schizoprenia (N=20) Bipolar disorder (N=20) P
Years 36.6± 7.69 39.75± 7.86 42.45± 6.58 0.051
Females/males 11/9 6/14 13/7 0.074
Ethnic group Caucasian Caucasian Caucasian
Smoking (n/y) 17/3 11/9 8/11 0.018
BMI 23.66± 3.13 26.85± 6.20 26.85± 4.15 0.054
Age of onset — 25.45± 6.57 27.44± 6.13 0.318
Length of illness (years) — 14.7± 9.4 14.56± 6.43 0.714
Hospitalizations (n) — 3.75± 5.56 5.32± 7.07 0.557
Chlorpromazine equivalent — 237.04 50.5 0.002
Antipsychotic lifetime (years) — 10.42± 8.36 5.91± 7.03 0.061
Mood stabilizer lifetime (years) — — 8.54± 5.21
GAF 82.25± 4.85 45± 11.49 58.79± 13.67 0.0001
BPRS
Total — 45.83± 12.03 32.22± 5.83 0.006
Anxiety and depression — 11.93± 5.12 11± 4.00 0.813
Negative symptoms — 12.7± 4.82 7.44± 0.73 0.0005
Positive symptoms — 12.75± 6.07 8.4± 6.35 0.026
Mania — 12.75± 3.99 10.22± 1.99 0.077
BRMRS — — 2.95± 5.2
HDRS (21 items) — — 14.21± 11.78
Abbreviations: BMI, body mass index; BPRS, Brief Psychiatric Rating Scale; BRMRS, Bech–Rafaelsen Mania Rating Scale; GAF, global assessment of functioning;
HDRS, Hamilton Depression Rating Scale; n/y, no/yes.
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Real-time PCR
The cDNA from ~100 ng of starting RNA was used for real-time (RT) PCR
using Pre-developed Taqman Assay Reagents (Applied Biosystems, Monza,
Italy) on an ABI Prism 7700 thermal cycler (Applied Biosystems) according
to the manufacturer's protocol. Reactions were performed in 25 μl volume
and each reaction contained the FAM-labeled probe and primers for the
given target. Human GAPDH was used as the housekeeping gene.
Threshold parameters were maintained constant for GAPDH and for each
target throughout the study. Relative quantiﬁcation was obtained using
the same reference sample, cDNA from peripheral blood mononuclear
cells from a healthy blood donor, in which all targets were ampliﬁable,
throughout the study, and results were expressed as arbitrary units (a.u.),
according to the manufacturer's instructions (User Bulletin no. 2, Applied
Biosystems). The following mRNAs have been quantiﬁed: chemokine (ccl1,
ccl2, ccl3, ccl4, ccl5, ccl20, ccl22 and cxcl10), chemokine receptors (ccr3, ccr4,
ccr5, ccr6, ccr7 and cxcr5), cytokines (il1α, il1β, il4, il6, il10, il17, ifnγ, tgfβ and
tnfα) and T-reg cell markers (CD25/il2ra and foxp3).
Auto-antibodies
On paired serum samples obtained from patients and controls, the clinical
laboratory of the San Raffaele Scientiﬁc Institute, Laboraf, measured
antinuclear antibodies (using indirect immunoﬂuorescence): anti-
cardiolipin (IgG and IgM), anti-transglutaminase (IgA and IgG), anti-
B2microglubulin, anti-tireoperoxidase and anti-tireoglobulin antibodies
(using standard enzyme-linked immunosorbent assay).
Statistics
All statistical analyses were performed using the STATA 13 (College Station,
TX, USA). Continuous variables were described as the mean and s.d. or
median and range, based on the results of the Shapiro–Wilk test.
Categorical variables were described as frequencies and percentages and
Χ2 or Fisher exact test were used to compare distributions. To compare age
and body mass index among the three diagnostic groups, analysis of
variance was used after verifying the assumptions. To compare GAF score
and to explore differences in marker levels, Kruskal–Wallis test was used, as
there was no homogeneity of variances. Two group comparisons were
made using the Mann–Whitney test. Spearman’s correlation analyses were
used to explore possible associations between quantitative variables.
Bonferroni’s correction for multiple comparisons was applied to all the
analyses.
RESULTS
We measured peripheral blood mononuclear cell mRNA levels of
ccl1, ccl2, ccl3, ccl4, ccl5, ccl20, ccl22, cxcl10, ccr3, ccr4, ccr5, ccr6,
ccr7, cxcr5, il1α, il1β, il4, il6, il10, il17, ifnγ, tgfβ tnfα, CD25/il2ra and
foxp3 in HCs, patients affected by SCZ and in patients affected by
BD, trying to group them according to their most likely cell of
origin.
M1 and M2 monocyte activation markers
We considered il1α, il1β, il6, ccl3, ccl1, ccl22 and il10 as innate
immune cell markers.
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Figure 1. The M1 markers il6 (a) and ccl3 (b) differed among the three groups (P= 0.009 and P= 0.007, respectively; Kruskal–Wallis test,
Bonferroni-corrected) and were upregulated in bipolar disorder patients (BD) compared with both healthy controls (HCs; P= 0.03 and
P= 0.002, respectively) and schizophrenia patients (SCZ; P= 0.024 and P= 0.021, respectively; Mann–Whitney U-test, Bonferroni-corrected).
The M2 markers ccl1 (c), ccl22 (d) and il10 (e) signiﬁcantly differed among the groups (P= 0.005, P= 0.002 and P= 0.009, respectively;
Kruskal–Wallis test, Bonferroni-corrected) and were downregulated in individuals with BD compared with both HC (P= 0.01, P= 0.001 and
P= 0.09, respectively) and SCZ subjects (P= 0.02, P= 0.05 and P= 0.011, respectively; Mann–Whitney U-test, Bonferroni-corrected).
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The M1 markers il6 and ccl3, but not il1α, and il1β, signiﬁcantly
differed among the three groups (P= 0.009 and P= 0.007,
respectively, Kruskal–Wallis test, Bonferroni-corrected), being
higher in BD patients compared with both HC (P= 0.03 and
P= 0.002, respectively) and SCZ patients (P= 0.024 and P= 0.021,
respectively; Mann–Whitney U-test, Bonferroni-corrected; Figures
1a and b).
As per the M2 markers, ccl1, ccl22 and il10 signiﬁcantly differed
across the three groups (P= 0.005, P= 0.002 and P= 0.009,
respectively; Kruskal–Wallis test, Bonferroni-corrected), being
signiﬁcantly lower in individuals with BD compared with both
control (P= 0.01, P= 0.001 and P= 0.09, respectively) and SCZ
subjects (P= 0.02, P= 0.05 and P= 0.011, respectively; Mann–-
Whitney U-test, Bonferroni-corrected) (Figures 1c–e). In contrast,
no abnormal values were found in subjects with SCZ for any M1 or
M2 markers (P40.05; Mann–Whitney U-test, Bonferroni-corrected).
In Table 2, a tentative classiﬁcation of the analyzed immune
genes according to the M1/M2 paradigm is reported. However, it
should be kept in mind that genes that have been linked to
monocyte/macrophage polarization can have important roles in
other cell types such as T-helper cells.
Th1, Th2 and T-reg cell markers
The Th1 chemokine receptor ccr5 signiﬁcantly differed across the
three groups (P= 0.015; Kruskal–Wallis test, Bonferroni-corrected),
being lower in BD patients compared with HC (P= 0.02) but not
with SCZ patients (P= 0.26; Mann–Whitney U-test, Bonferroni-
corrected; Figure 2a). No differences were found for the other
putative Th1 markers ccl3 (which is also a M1 marker, as
mentioned above), ccl5, ccl20, ifnγ, cxcl10, tnfα across the three
groups (P40.05; Kruskal–Wallis test, Bonferroni-corrected).
Moreover, the prototypical Th2 cytokine ccl2 and il4 mRNAs
were signiﬁcantly different among the three groups (P= 0.036 and
P= 0.002, respectively; Figures 2b and c), whereas no differences
were found for the other Th2 marker mRNA levels including il10
(which is also a M2 marker, as mentioned above), ccl4, ccl11, ccr3,
ccr4 (P40.05; Kruskal–Wallis test, Bonferroni-corrected). In parti-
cular, BD patients had signiﬁcantly lower ccl2 compared with
control and SCZ subjects (P= 0.006 and P= 0.003, respectively)
and higher il4 signiﬁcantly compared with HC (P= 0.04) but not to
SCZ patients (P= 0.145; Mann–Whitney U-test, Bonferroni-
corrected).
Finally, the T-reg cell marker tgfβ signiﬁcantly differed across
groups (P= 0.001; Kruskal–Wallis test, Bonferroni-corrected) being
signiﬁcantly lower in BD patients compared with both HC and SCZ
individuals (P= 0.004 and P= 0.007, respectively; Mann–Whitney
U-test, Bonferroni-corrected; Figure 2d). No signiﬁcant differences
of any other T-reg cells markers, including foxp3, il2ra (CD25), nor
of ccr7 mRNAs, across the three groups were found (P40.05;
Kruskal–Wallis test, Bonferroni-corrected).
No signiﬁcant differences were found between subjects with
SCZ and HC for any T-cell markers (P40.05; Mann–Whitney U-test,
Bonferroni-corrected).
Marker correlations
Spearman correlation analyses (Bonferroni-corrected) were con-
ducted among the immunological markers in each group. CD25/
il2ra and foxp3 signiﬁcantly directly correlated in each group
(controls: Spearman’s rho = 0.739, Po0.001; bipolar patients:
Spearman’s rho = 0.854, Po0.0001; SCZ patients: Spearman’s
rho = 0.681, Po0.0001). Moreover, il1a signiﬁcantly directly
associated with cxcl10 in subjects with BD (Spearman’s rho =
0.651, P= 0.025) and with il1b in those with SCZ (Spearman’s
rho = 0.611, P= 0.043).
Clinical variable impact
Immunological variables did not show any signiﬁcant association
with GAF score and body mass index in the three groups or with
number of prior hospitalizations, Brief Psychiatric Rating Scale
subscores (anxiety and depression, negative symptoms, positive
symptoms and mania) and medications (both dosages and
lifetime administration of antipsychotics and mood stabilizers) in
BD and SCZ patients (Spearman's correlation analyses, P40.05,
Bonferroni-corrected). In addition, no signiﬁcant differences were
found between smokers and non-smokers for the markers that
had different results across the three groups (P40.05; Mann–-
Whitney U-test, Bonferroni-corrected).
Anti-cardiolipin IgGs are more frequent among bipolar patients
In light to detect signs of a dis-immune status in BD and SCZ, we
measured a small panel of auto-antibodies including antinuclear
antibodies, IgG and IgM anti-cardiolipin antibodies, anti-β2
microglobulin antibodies, IgG and IgA anti-transglutaminase
antibodies, anti-thyreoglobulin and anti-thyreoperoxidase antibo-
dies. We found no differences among groups for all these
autoreactivities but for anti-cardiolipin IgGs, where the only four
positive samples were clustered in the group of BD patients
(P= 0.030; Fisher exact test). Further, all samples have been used
to stain mouse cerebellum, a typical procedure used in diagnostic
neuroimmunology to detect antineural antigen autoreactivity. No
reactivity, however, was detected, neither in HCs nor in patients
affected by either BD or SCZ (not shown).
DISCUSSION
We interrogated blood samples from a relatively small but very
selected and homogenous cohort of patients affected by major
Table 2. Classiﬁcation of the analyzed immune genes according to
the M1/M2 paradigm (see references 62–66)
Gene Phenotype
ccl1 M2b
ccl2 Both M1 and M2
ccl3 M1
ccl4 M1
ccl5 M1
ccl11 M2
ccl20 No conﬁrmed association
ccl22 M2
cxcl10 M1
cc3 No conﬁrmed association
ccr4 No conﬁrmed association
ccr5 M1
ccr6 No conﬁrmed association
ccr7 M1
cxcr5 No conﬁrmed association
il1α M1
il1β M1
il4 M2
il6 M1
il10 M2
il17 No conﬁrmed association
ifnγ M1
tgfβ No conﬁrmed association
tnfα M1
CD25/il2ra No conﬁrmed association
foxp3 No conﬁrmed association
It should be noted that not all the analyzed genes have been clearly linked
to one of the two activation phenotypes. In addition, genes that have been
linked to monocyte/macrophage polarization can have important roles in
other cell types such as T-helper cells.
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psychoses, either BD or SCZ, to identify an immune-signature in
comparison with age and gender-matched healthy individuals. We
found a number of myeloid cell markers to be modulated in
patients affected by BD as compared with SCZ patients and HCs.
Myeloid cells have been recently in the spotlight of innate
immunity studies because of their newly discovered ability to have
different functional phenotypes. In macrophages, this plasticity
has been simpliﬁed in two main polarization types: M1 macro-
phages, regarded as pro-inﬂammatory, phagocytic, potentially
tissue damaging; and M2 macrophages, considered immunomo-
dulatory, tissue remodeling and pro-reparative.40–43 Macrophages
derive from circulating monocytes, and it is not completely clear
whether circulating macrophages can be polarized. Nevertheless,
we, as many authors in other diseases, found a coherent M1
signature, implying also the decrease of M2 markers, in the
peripheral blood of bipolar patients. This is not new: myeloid cell
alteration has been already reported in bipolar and psychotic
patients. It is interesting that also the ﬁrst reports on monocyte
modulation in depressed patients describe the decrease in beta-2
adrenoceptors,44 and increased phagocytosis,45 phenomena
associated today to M1 skewing.40,46 No doubt, however, that
the ﬁeld has been pioneered by Drexhage et al.23 describing a
raised number of pro-inﬂammatory (M1) monocytes in bipolar
patients, by several technical means.47–49 Thus, our study is the
ﬁrst independent conﬁrmation of an M1 signature in monocytes
from peripheral blood mononuclear cells of bipolar patients
without medical comorbidities and strengthens the case for the
identiﬁcation of a subgroup of BD patients who may beneﬁt by
anti-inﬂammatory therapies. Altered monocyte cytokine proﬁle
can be the result of an immune or inﬂammatory process occurring
in the central nervous system. For example, substance P release
has been linked to major depression50 and is also well known to
activate monocytes.51 On the other hand, a large literature has
shown how peripheral pro-inﬂammatory cytokines induce depres-
sion behavior on both experimental conditions and human
patients.52 Available data do not indicate whether the M1 shift
in monocytes from bipolar patients is cause or consequence of the
disease. In the latter case, anti-inﬂammatory therapeutic strategies
would be less relevant. If, however, this monocyte modulation
precedes disease onset, it is most likely connected to its etiology,
and its therapeutic targeting may be extremely efﬁcacious.
Considering the T-helper markers, the Th1 chemokine receptor
ccr5 was downregulated in BD, whereas the prototypical Th2
marker il4 was upregulated in BD, suggesting a Th1/Th2 shift in
BD. However, the downregulaton of ccl2, considered a Th2 marker,
limits the possibility to fairly discuss this shift. Nonetheless, ccl2 is
mostly released by monocytes and might very well be considered
in the context of the M1 shift described above, thus leading to a
more coherent picture. Future larger studies in BD should further
investigate the potential Th1/Th2 shift in BD. Interestingly, as
already been described, we also detected a downregulation of
tgfβ in BD,53,54 which is considered a potent anti-inﬂammatory
mediator.55 Therefore, reduced tgfβ expression may expose the
brain of subjects with BD to an increased susceptibility to
neurotoxicity. In contrast, we were not able to conﬁrm alterations
in the expression of the major T-regulatory markers (that is, CD25
and foxp3) previously reported.56 However, in this perspective,
downregulated tgfβ may cause a functional impairment of these
cells, being released by a variety of leukocytes including
T-reg cells.
Finally, anti-cardiolipin auto-antibodies were detected only
among BD patients. However, relatively low frequency and sample
size do not allow deﬁnitive conclusions. Nonetheless, it has been
reported that anti-phospholipid auto-antibodies, of which anti-
cardiolipin auto-antibodies are a subset, are associated with
BD.57,58 Therefore, this suggestive ﬁnding clearly needs to be
conﬁrmed in a larger series of samples.
Some limitations of our study must be taken into account in the
interpretation of these results: ﬁrst, the mean duration of illness, as
our patient groups were chronically ill, the cross-sectional design
of the study and the relatively small sample size of our population.
Second, elevated cytokine levels might also reﬂect general
medical comorbidity and lifestyle-related factors of psychiatric
disorders such as smoking, alcohol use and poor physical
condition. Smoking was differently present in the three groups,
nevertheless all our patients had no medical comorbidities. Third,
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Figure 2. The prototypical Th1 cytokine ccr5 (a) signiﬁcantly differed across the three groups (P= 0.015; Kruskal–Wallis test, Bonferroni-
corrected) and was downregulated in BD patients compared with HC (P= 0.02) but not to SCZ patients (P= 0.26; Mann–Whitney U-test,
Bonferroni-corrected). The prototypical Th2 cytokine ccl2 (b) and il4 mRNA (c) and the T-regulatory cell marker tgfβ (d) were signiﬁcantly
different among the three groups (P= 0.036, P= 0.002 and P= 0.001, respectively). In particular, BD patients had downregulated ccl2 and tgfβ
compared with controls (P= 0.006 and P= 0.004, respectively) and individuals with SCZ (P= 0.003 and P= 0.007, respectively) and upregulated
il4 compared with HC (P= 0.04) but not to SCZ patients (P= 0.145; Mann–Whitney U-test, Bonferroni-corrected).
Monocyte and T-cell markers in bipolar disorder
P Brambilla et al
5
© 2014 Macmillan Publishers Limited Translational Psychiatry (2014), 1 – 7
our study was naturalistic and most of patients were receiving
psychotropic drugs, the majority was on atypical antipsychotics.
These medications are thought not to induce but rather correct
the abnormal inﬂammatory set-point of patient monocytes.59,60
Regarding BD, half of them were treated also with mood
stabilizers, four of them were on lithium, considered in general
to be anti-inﬂammatory.61 Thus, we cannot rule out that some of
the ﬁndings may have been inﬂuenced by medications.
Future larger studies should further investigate the relevance of
M1/M2 and potential Th1/Th2 signature in BD, trying to correlate it
to episode type, treatment and outcome measures and, possibly,
to brain connectivity.
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